XTRA:MRKPharmaceuticals
Merck KGaA (XTRA:MRK) Expands Into Precision Cardiology, Is The Upside Already Priced In?
Merck KGaA (XTRA:MRK) has moved deeper into precision cardiology, committing a $50 million upfront payment and a build-to-buy structure with Saturnus Bio that targets rare genetic cardiomyopathies lacking approved therapies.
See our latest analysis for Merck KGaA.
Merck KGaA’s recent cardiology deal lands at a time when momentum in the stock has been picking up, with a 30 day share price return of 8.84% and a 90 day share price return of 32.33%. The 1 year total shareholder return of 33.23%...